Explore the Agenda
8:00 am Check-In & Coffee
Grab a coffee and sit down with key contacts in the hour before the conference begins
8:55 am Chair’s Opening Remarks
Unraveling Treg Development & Function Pathways to Advance Therapeutic Innovation
9:00 am NEW DATA: Exploring Treg Functionality & Immune Cell Interactions Induced by Treg Therapies to Enhance Therapeutic Efficacy
- Unearthing the mechanisms that induce Treg proliferation and enhance function
- Investigating the role of chemokines in immune regulation to understand how Tregs impact T effector and surrounding immune cells
- Discussing if Tregs alone have enough functionality and therapeutic impact to combat disease
9:30 am NEW DATA: Decoding Thymic-Derived (Natural) Treg Development Pathways to Uncover the Molecular Drivers for Treg Development
- Gaining insights into the environmental stimuli that stimulate the transcription factory to produce Tregs
- Understanding the molecular pathways that drive thymic Treg generation to better inform therapeutic development
- Exploring the cellular precursors of Foxp3+ Tregs, including the involvement of TGF-β to unlock insights into Treg development
10:00 am NEW DATA: Unlocking Treg Functional Pathways to Drive Therapeutic Innovation
- Investigating the key drivers and surface molecules required for Treg functionality
- Highlighting necessity for the cGAS/STING/type I IFN axis for induction of tolerance (via Treg induction) by antigen-loaded PLGA nanoparticles
- Exploring novel therapies that have leveraged these mechanisms of action to regulate the immune response
10:30 am Morning Break & Networking
11:00 am Presentation & Discussion: Utilizing Molecular Pathways to Sustain Treg Stability & Immune Control
- Understanding the molecular pathways that impact Treg phenotype to manipulate the inflammatory environment in our favor
- Harnessing novel approaches to sustain phenotypic stability post-thymic development
- Discussing strategies to engineer TCR specificity and clonality in Treg function
Enhancing Treg Targeting & Engineering Strategies to Refine Durability, Precision & Prevent Treatment Rejection
11:45 am NEW DATA: Engineering Cytokine Bias to Enhance Precise Treg Targeting & Expansion
- Apply structural and mechanistic insights to create cytokine/antibody fusion proteins that direct IL-2 activity towards Tregs
- Elucidate key design principles critical to the functional behavior of IL-2-based cytokine/antibody fusion proteins
- Demonstrate translational potential of cytokine/antibody fusion proteins in preclinical models of colitis and hemophilia
12:15 pm Lunch Break & Networking
1:15 pm Roundtable Discussion: Engineering Next-Generation Tregs to Advance Treg Therapeutic Development
- Investigating engineering Treg cells from CD4+ and iPSC precursors to understand the impact on efficacy
- Examining engineering strategies required to achieve durable Treg stability in vivo for long-term efficacy
- Engineering CAR-Tregs and Allogeneic Tregs for potential therapies of autoimmune and transplant disease
- Growth factor and durability support strategies for long term Treg persistence in patients
2:15 pm Targeting Autoantigens to Overcome Allogeneic Treg Rejection & Enhance Therapeutic Success
- Discussing interactions between the immune system and allogeneic Tregs to identify rejection mechanisms
- Investigating opportunities to define and target autoantigens key to allogeneic Treg rejection
- Strategies to remove or modify autoantigens to enhance persistence and prevent treatment rejection